Figure 4.
Four-year CIRs of relapse by type of relapse and CNS status. (A) AALL0434 CIR of isolated marrow relapse: CNS-1, 3.4% ± 0.6%; CNS-2, 3.2% ± 1.2%; and CNS-3, 3.1% ± 1.8% (P = .977). (B) AALL0434 CIR of combined marrow and CNS relapse: CNS-1, 1.1% ± 0.4%; CNS-2, 1.4% ± 0.8%; and CNS-3, 1.0% ± 1.0% (P = .963). (C) AALL0434 CIR of isolated CNS relapse: CNS-1, 1.0% ± 0.4%; CNS-2, 4.2% ± 1.4%; and CNS-3, 11.0% ± 3.2% (P < .0001). (D) AALL1231 CIR of isolated marrow relapse: CNS-1, 3.4% ± 0.9%; CNS-2, 1.5% ± 1.1%; and CNS-3, 8.4% ± 4.9% (P = .18). (E) AALL1231 CIR of combined marrow and CNS relapse: CNS-1, 0.7% ± 0.4%; CNS-2, 2.3% ± 1.3%; and CNS-3, 0.0% ± 0.0% (P = .45). (F) AALL1231 CIR of isolated CNS relapse: CNS-1, 2.8% ± 0.8%; CNS-2, 5.3% ± 2.0%; and CNS-3, 4.7% ± 3.3% (P = .34).

Four-year CIRs of relapse by type of relapse and CNS status. (A) AALL0434 CIR of isolated marrow relapse: CNS-1, 3.4% ± 0.6%; CNS-2, 3.2% ± 1.2%; and CNS-3, 3.1% ± 1.8% (P = .977). (B) AALL0434 CIR of combined marrow and CNS relapse: CNS-1, 1.1% ± 0.4%; CNS-2, 1.4% ± 0.8%; and CNS-3, 1.0% ± 1.0% (P = .963). (C) AALL0434 CIR of isolated CNS relapse: CNS-1, 1.0% ± 0.4%; CNS-2, 4.2% ± 1.4%; and CNS-3, 11.0% ± 3.2% (P < .0001). (D) AALL1231 CIR of isolated marrow relapse: CNS-1, 3.4% ± 0.9%; CNS-2, 1.5% ± 1.1%; and CNS-3, 8.4% ± 4.9% (P = .18). (E) AALL1231 CIR of combined marrow and CNS relapse: CNS-1, 0.7% ± 0.4%; CNS-2, 2.3% ± 1.3%; and CNS-3, 0.0% ± 0.0% (P = .45). (F) AALL1231 CIR of isolated CNS relapse: CNS-1, 2.8% ± 0.8%; CNS-2, 5.3% ± 2.0%; and CNS-3, 4.7% ± 3.3% (P = .34).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal